Please use this identifier to cite or link to this item:
Title: Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis
Author: Pascual, Tomás
González-Farre, Blanca
Teixidó, Cristina
Oleaga Zufiría, Laura
Oses, Gabriela
Ganau, Sergi
Chic, Núria
Riu Viladoms, Gisela
Adamo, Barbara
Galván, Patricia
Vidal Losada, Maria Jesús
Soy Muner, Dolors
Urbano Ispizua, Álvaro
Muñoz Mateu, Montserrat
Prat Aparicio, Aleix
Keywords: Càncer de mama
Receptors d'hormones
Expressió gènica
Breast cancer
Hormone receptors
Gene expression
Issue Date: 7-Jun-2019
Publisher: American Society of Clinical Oncology
Abstract: Breast cancer is a biologically and clinically heterogeneous disease, and patients with similar clinical stage have markedly different outcomes. Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2).1,2 This subtype represents 15% to 20% of all breast cancers and is associated with the worst outcome of all subtypes, with greater tendency to distant recurrence in general and visceral metastasis in particular, including brain metastasis.3,4 To date, chemotherapy remains the standard of care for TNBC
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Oncology, 2019
Related resource:
ISSN: 0732-183X
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
698028.pdf1.28 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.